中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2071-2074

Value of lymphocyte subset testing in predicting HBsAg decline in chronic hepatitis B patients receiving antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.09.014

  • Department of infectious Diseases, Henan Provincial People's Hospital, Zhengzhou 450003, China

Research funding:

Tianqing Liver Disease Research Foundation of Chinese Foundation for Hepatitis Prevention and Control (TQGB20190252)

  • Received Date: 2021-02-22
  • Accepted Date: 2021-04-30
  • Published Date: 2021-09-20
    Abstract
  •   Objective  To investigate whether there are differences in lymphocyte subsets between chronic hepatitis B (CHB) patients receiving different antiviral treatment regimens, and to determine related predictive factors for HBsAg decline.  Methods  A retrospective analysis was performed for 68 treatment-experienced CHB patients who attended the outpatient service in Department of Infectious Diseases, Henan Provincial People's Hospital, from October to December 2019, and according to the antiviral treatment regimen, they were divided into PEG-IFNα treatment group with 10 patients, PEG-IFNα+nucleos(t)ide analogues (NAs) treatment group with 21 patients, and NAs treatment group with 37 patients. Related data were recorded, including demographic features, blood routine, albumin, HBsAg, and measurement of lymphocyte subsets. A one-way analysis of variance was used for comparison of normally distributed continuous data between groups, and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; the multivariate logistic regression analysis was used to investigate independent influencing factors for HBsAg decline.  Results  There were significant differences between the three groups in HBsAg decline (H=8.348, P=0.015), absolute value of lymphocytes (F=4.643, P=0.013), and T lymphocyte count (F=7.721, P=0.001). The multivariate logistic regression analysis showed that sex (odds ratio [OR]=0.227, 95% confidence interval [CI]: 0.059-0.878, P=0.032), age (OR=0.931, 95%CI: 0.868-0.999, P=0.047), antiviral treatment regimen (PEG-IFN-α treatment group vs NAs treatment group: OR=9.600, 95%CI: 1.982-46.498, P=0.005; PEG-IFN-α+NAs treatment group vs NAs treatment group: OR=4.800, 95%CI: 1.336-17.243, P=0.016), and T lymphocyte count (OR=0.804, 95%CI: 0.684-0.944, P=0.008) were independent influencing factors for HBsAg decline.  Conclusion  For CHB patients receiving PEG-IFNα alone or in combination with NAs, monitoring of lymphocyte subsets during the treatment process may help to judge HBsAg decline, and the lower the absolute value of T lymphocytes, the greater the possibility of HBsAg decline.

     

    • FullText(HTML)
  • loading
    • References(12)
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    PAN J, ZHANG M, YAO TT, et al. Efficiency and influencing factors of interferon therapy for 1-6 years old children with chronic hepatitis B[J]. Int J Virol, 2020, 27(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009.

    潘静, 张敏, 姚甜甜, 等. 干扰素治疗1~6岁慢性乙型肝炎的疗效及影响因素[J]. 国际病毒学杂志, 2020, 27(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009.
    [3]
    WU D, WANG P, HAN M, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: The Endeavor study[J]. Hepatol Int, 2019, 13(5): 573-586. DOI: 10.1007/s12072-019-09956-1.9/j.issn.1001-5256.2019.12.007.
    [4]
    YIP TC, CHAN HL, WONG VW, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance[J]. J Hepatol, 2017, 67(5): 902-908. DOI: 10.1016/j.jhep.2017.06.019.9/j.issn.1001-5256.2019.12.007.
    [5]
    JANSSEN HL, van ZM, SENTURK H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial[J]. Lancet, 2005, 365(9454): 123-129. DOI: 10.1016/S0140-6736(05)17701-0.9/j.issn.1001-5256.2019.12.007.
    [6]
    LAU GK, PIRATVISUTH T, LUO KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2005, 352(26): 2682-2695. DOI: 10.1056/NEJMoa043470.9/j.issn.1001-5256.2019.12.007.
    [7]
    MARCELLIN P, BONINO F, YURDAYDIN C, et al. Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int, 2013, 7(1): 88-97. DOI: 10.1007/s12072-012-9343-x.9/j.issn.1001-5256.2019.12.007.
    [8]
    CHEVALIEZ S, HÉZODE C, BAHRAMI S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely[J]. J Hepatol, 2013, 58(4): 676-683. DOI: 10.1016/j.jhep.2012.11.039.9/j.issn.1001-5256.2019.12.007.
    [9]
    HU P, SHANG J, ZHANG W, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. J Clin Transl Hepatol, 2018, 6(1): 25-34. DOI: 10.14218/JCTH.2017.00072.9/j.issn.1001-5256.2019.12.007.
    [10]
    MCNAB F, MAYER-BARBER K, SHER A, et al. Type Ⅰ interferons in infectious disease[J]. Nat Rev Immunol, 2015, 15(2): 87-103. DOI: 10.1038/nri3787.9/j.issn.1001-5256.2019.12.007.
    [11]
    MICCO L, PEPPA D, LOGGI E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B[J]. J Hepatol, 2013, 58(2): 225-233. DOI: 10.1016/j.jhep.2012.09.029.
    [12]
    WANG HL, DENG GH. Functional status of hepatitis B virus-specific T cells in patients with chronic hepatitis B virus infection: Exhausted or silenced?[J]. J Clin Hepatol, 2020, 36(5): 980-982. DOI: 10.3969/j.issn.1001-5256.2020.05.005.

    王昊亮, 邓国宏. 慢性HBV感染者病毒特异性T淋巴细胞: 耗竭还是沉默?[J]. 临床肝胆病杂志, 2020, 36(5): 980-982. DOI: 10.3969/j.issn.1001-5256.2020.05.005.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (410) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return